MabSpace Biosciences
2013
FOUNDED
PRIVATE
STATUS
Series B
LATEST DEAL TYPE
$40M
LATEST DEAL AMOUNT
3
INVESTORS
Description
Developer of antibody based therapeutics designed to treat cancer and fibrotic disorders affecting lung, kidney and liver. The company's therapeutics are based on its proprietary immune tolerance breaking technology (IMBT) that generates lead antibodies with diverse epitopes that targets different components of the tumor microenvironment, enabling physicians to treat cancer and fibrotic diseases with a better medical outcome.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 218 Xinghu Street
- Biobay B6-501
- Suzhou, 215123
- China
+86 0512 0000 0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore MabSpace Biosciences’s full profile, request a free trial.
MabSpace Biosciences Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series B) | 09-May-2018 | $40M | 0000 | Completed | Startup | |
| 1. Early Stage VC (Series A) | 28-Oct-2015 | 0000 | 0000 | Completed | Startup |
MabSpace Biosciences Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| King Star Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Sequoia Capital China | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Lilly Asia Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
MabSpace Biosciences Executive Team (3)
MabSpace Biosciences Board Members (1)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Xueming Qian Ph.D | MabSpace Biosciences | Founder, Chairman & Chief Executive Officer | 000 0000 |